Search Results - "Stenehjem, David"

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer by Stenehjem, David D, Tran, Dao, Nkrumah, Michael A, Gupta, Shilpa

“…Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40…”
Get full text

Diagnosis and treatment of cancer‐related anemia by Gilreath, Jeffrey A., Stenehjem, David D., Rodgers, George M.

“…Cancer‐related anemia (CRA) is due to multiple etiologies, including chemotherapy‐induced myelosuppression, blood loss, functional iron deficiency,…”
Get full text

Tumor mutational burden in lung cancer: a systematic literature review by Willis, Connor, Fiander, Michelle, Tran, Dao, Korytowsky, Beata, Thomas, John-Michael, Calderon, Florencio, Zyczynski, Teresa M, Brixner, Diana, Stenehjem, David D

“…To assess the association of tumor mutational burden (TMB) with clinical outcomes, other biomarkers and patient/disease characteristics in patients receiving…”
Get full text

Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma by Murugappan, Meena N., King-Kallimanis, Bellinda L., Bhatnagar, Vishal, Kanapuru, Bindu, Farley, Joel F., Seifert, Randall D., Stenehjem, David D., Chen, Ting-Yu, Horodniceanu, Erica G., Kluetz, Paul G.

“…Purpose The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items…”
Get full text

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma by Stenehjem, David D, Hahn, Andrew W, Gill, David M, Albertson, Daniel, Gowrishankar, Banumathy, Merriman, Joseph, Agarwal, Archana M, Thodima, Venkata, Harrington, Erik B, Au, Trang H, Maughan, Benjamin L, Houldsworth, Jane, Pal, Sumanta K, Agarwal, Neeraj

“…First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine…”
Get full text

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia by Pokorny, Rebecca, Stenehjem, David D., Gilreath, Jeffrey A.

“…Objective Oral tyrosine kinase inhibitors (TKIs) are first line therapy for chronic myeloid leukemia (CML). A complete cytogenetic response (CCyR) correlates…”
Get full text

Cancer incidence in immunocompromised patients: a single-center cohort study by Ilham, Sabrina, Willis, Connor, Kim, Kibum, Chung, Karen C, Wood, Brenda M, Tan, Malinda S, Tan, Chia Jie, Nguyen, Danielle T, Brixner, Diana I, Stenehjem, David D

“…Diminished immune defense plays an important role in cancer development. Cancer risk in immunocompromised patients may differ. Identifying individuals with…”
Get full text

Integrating pharmacogenetic testing via medication therapy management in an outpatient family medicine clinic by Brown, Jacob T, MacDonald, Danielle, Yapel, Ann, Luczak, Tiana, Hanson, Anna, Stenehjem, David D

“…Pharmacogenetic (PGx) implementation has lagged behind the development of drug/gene pair guidelines. This was a prospective study assessing the integration of…”
Get full text

Applying an equity lens to pharmacogenetic research and translation to under‐represented populations by Luczak, Tiana, Stenehjem, David, Brown, Jacob

“…Since the publication of the Human Genome Project, genetic information has been used as an accepted, evidence‐based biomarker to optimize patient care through…”
Get full text

Impact of a genetic counseling requirement prior to genetic testing by Stenehjem, David D, Au, Trang, Sainski, Amy M, Bauer, Hillevi, Brown, Krystal, Lancaster, Johnathan, Stevens, Vanessa, Brixner, Diana I

“…Genetic counseling by a Genetic Counselor (GC) is a requirement prior to genetic testing for cancer susceptibility genes (GC-mandate policy) for some insurers…”
Get full text

Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma by Hahn, Andrew W., Froerer, Camryn, VanAlstine, Sidney, Rathi, Nityam, Bailey, Erin B., Stenehjem, David D., Agarwal, Neeraj

“…Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) are a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome…”
Get full text

Panobinostat for the treatment of multiple myeloma: the evidence to date by Bailey, Hanna, Stenehjem, David D, Sharma, Sunil

“…Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow. Survival of patients diagnosed with myeloma has significantly…”
Get full text

Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data by Rivers, Zachary T., Parsons, Helen M., Jacobson, Pamala A., Kuntz, Karen M., Farley, Joel F., Stenehjem, David J.

“…United States clinical practice guidelines for metastatic colorectal cancer recommend use of medications impacted by genetic variants but do not recommend…”
Get full text

Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? by Biltaji, Eman, Walker, Brandon, Au, Trang H, Rivers, Zachary, Ose, Jennifer, Li, Christopher I, Brixner, Diana I, Stenehjem, David D, Ulrich, Cornelia M

“…Inherited genetic variants can modify the cancer-chemopreventive effect of aspirin. We evaluated the clinical and economic value of genotype-guided aspirin use…”
Get full text

Perceptions of pharmacogenetic exceptionalism and the implications for clinical management within an electronic health record by Butler, Tiana, Brown, Jacob, Jacobson, Pamala A., Stenehjem, David

“…Genetic exceptionalism refers to a concept that genetic information is distinct from other health data and therefore should have additional safety guards in…”
Get full text

BRCA testing and outcomes in women with breast cancer by Stenehjem, David D., Telford, Claire, Unni, Sudhir K., Bauer, Hillevi, Sainski, Amy, Deka, Rishi, Schauerhamer, Marisa B., Ye, Xiangyang, Tak, Casey R., Ma, Junjie, Dalvi, Tapashi B., Gutierrez, Lia, Kaye, James A., Tyczynski, Jerzy E., Brixner, Diana I., Biskupiak, Joseph E.

“…Main purpose Germline BRCA mutations ( BRCA m) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCA m…”
Get full text

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer by Weldon Gilcrease, G., Stenehjem, David D., Wade, Mark L., Weis, John, McGregor, Kimberly, Whisenant, Jonathan, Boucher, Kenneth M., Thorne, Kelli, Orgain, Nicole, Garrido-Laguna, Ignacio, Sharma, Sunil

“…Summary Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of…”
Get full text

Estimation of healthcare-related charges in women with BRCA mutations and breast cancer by Biskupiak, Joseph, Unni, Sudhir, Telford, Claire, Yoo, Minkyoung, Ye, Xiangyang, Deka, Rishi, Brixner, Diana, Stenehjem, David

“…Breast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and…”
Get full text

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib by Nelson, Kellie Lynn, Stenehjem, David, Driscoll, Meghan, Gilcrease, Glynn Weldon

“…A 60- to 65-year-old female on prior statin therapy was initiated on palbociclib and fulvestrant for the treatment of metastatic, hormone-receptor positive…”
Get full text

Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States by Stenehjem, David D., Lubinga, Solomon J., Gupte-Singh, Komal, Zhang, Ying, Le, Trong Kim, Penrod, John R., Smith, Cardinale B.

“…In phase 3 clinical trials, nivolumab prolonged overall survival (OS) compared to chemotherapy in patients with previously treated advanced non–small-cell lung…”
Get full text